{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:45:47Z","timestamp":1788860747472,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Public Health Research Foundation"},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corp.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00198-022-06570-0","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T11:33:30Z","timestamp":1665747210000},"page":"189-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture: final results of the Japanese Osteoporosis Intervention Trial-05"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7660-5562","authenticated-orcid":false,"given":"Satoshi","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitsugu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Mitomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaito","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruki","family":"Sone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshitaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Soen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"6570_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-004-1813-0","volume":"16","author":"PD Delmas","year":"2005","unstructured":"Delmas PD, Rizzoli R, Cooper C, Reginster JY (2005) Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the International Osteoporosis Foundation. Osteoporos Int 16:1\u20135","journal-title":"Osteoporos Int"},{"key":"6570_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, De Laet C et al (2005) Assessment of fracture risk. Osteoporos Int 16:581\u2013589","journal-title":"Osteoporos Int"},{"key":"6570_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"6570_CR4","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 104:1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"key":"6570_CR5","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1210\/jc.2011-3479","volume":"97","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Sugimoto T, Nakano T et al (2012) Randomized teriparatide [human parathyroid hormone (PTH) 1\u201334] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097\u20133106","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6570_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175329","volume":"12","author":"H Yamane","year":"2017","unstructured":"Yamane H, Takakura A, Shimadzu Y et al (2017) Acute development of cortical porosity and endosteal na\u00efve bone formation from the daily but not weekly short-term administration of PTH in rabbit. PLoS One 12(4):e0175329. https:\/\/doi.org\/10.1371\/journal.pone.0175329","journal-title":"PLoS One"},{"key":"6570_CR7","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"Eastell R, Nickelsen T, Marin F et al (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726\u2013736","journal-title":"J Bone Miner Res"},{"key":"6570_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00198-007-0485-y","volume":"19","author":"S Adami","year":"2008","unstructured":"Adami S, San Martin J, Mu\u00f1oz-Torres M et al (2008) Effect of raloxifene after recombinant teriparatide [hPTH(1\u201334)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 19:87\u201394","journal-title":"Osteoporos Int"},{"key":"6570_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1185\/03007995.2012.761956","volume":"29","author":"T Sugimoto","year":"2013","unstructured":"Sugimoto T, Shiraki M, Nakano T et al (2013) Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin 29:195\u2013203","journal-title":"Curr Med Res Opin"},{"key":"6570_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa050336","volume":"353","author":"DM Black","year":"2005","unstructured":"Black DM, Bilezikian JP, Ensrud KE et al (2005) One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis. N Engl J Med 353:555\u2013565","journal-title":"N Engl J Med"},{"key":"6570_CR11","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00198-021-05996-2","volume":"32","author":"H Hagino","year":"2021","unstructured":"Hagino H, Sugimoto T, Tanaka S et al (2021) A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int 32:2301\u20132311","journal-title":"Osteoporos Int"},{"key":"6570_CR12","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00774-019-01074-0","volume":"38","author":"S Tanaka","year":"2020","unstructured":"Tanaka S, Mori S, Hagino H, Sugimoto T (2020) Design of a randomized trial of teriparatide followed by alendronate: Japanese Osteoporosis Intervention Trial-05 (JOINT-05). J Bone Miner Metab 38:412\u2013417","journal-title":"J Bone Miner Metab"},{"key":"6570_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00774-013-0447-8","volume":"31","author":"S Soen","year":"2013","unstructured":"Soen S, Fukunaga M, Sugimoto T et al (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31:247\u2013257","journal-title":"J Bone Miner Metab"},{"key":"6570_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S0197-2456(02)00242-8","volume":"23","author":"NW Scott","year":"2002","unstructured":"Scott NW, McPherson GC, Ramsay CR, Campbell MK (2002) The method of minimization for allocation to clinical trials: a review. Control Clin Trials 23:662\u2013674","journal-title":"Control Clin Trials"},{"key":"6570_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137\u20131148","journal-title":"J Bone Miner Res"},{"key":"6570_CR16","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155","journal-title":"Lancet"},{"key":"6570_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00774-015-0731-x","volume":"35","author":"K Ebina","year":"2017","unstructured":"Ebina K, Hashimoto J, Kashii M et al (2017) The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab 35:91\u201398","journal-title":"J Bone Miner Metab"},{"key":"6570_CR18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/jbm4.10054","volume":"2","author":"R Niimi","year":"2018","unstructured":"Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A (2018) Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial. JBMR Plus 2:289\u2013294","journal-title":"JBMR Plus"},{"key":"6570_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1186\/s12891-020-03771-8","volume":"21","author":"CH Park","year":"2020","unstructured":"Park CH, Yoo JI, Choi CH, Suh YS (2020) The impact of sequential therapy from short-term teriparatide to denosumab compared with denosumab alone in patients with osteoporotic hip fracture: a 1-year follow-up study. BMC Musculoskelet Disord 21:751","journal-title":"BMC Musculoskelet Disord"},{"key":"6570_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115516","volume":"139","author":"B Langdahl","year":"2020","unstructured":"Langdahl B (2020) Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone 139:115516","journal-title":"Bone"},{"key":"6570_CR21","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1002\/jbmr.2216","volume":"29","author":"C Muschitz","year":"2014","unstructured":"Muschitz C, Kocijan R, Fahrleitner-Pammer A et al (2014) Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density\u2014the CONFORS Study. J Bone Miner Res 29:1777\u20131785","journal-title":"J Bone Miner Res"},{"key":"6570_CR22","unstructured":"Japan Osteoporosis Society (2015) Japanese 2015 guidelines for prevention and treatment of osteoporosis (in Japanese). http:\/\/www.josteo.com\/ja\/index.html. Accessed 14 December 2021"},{"key":"6570_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00223-011-9499-8","volume":"89","author":"R Rizzoli","year":"2011","unstructured":"Rizzoli R, Reginster JY, Boonen S et al (2011) Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 89:91\u2013104","journal-title":"Calcif Tissue Int"},{"key":"6570_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res 31:16\u201335","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06570-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06570-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06570-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T02:02:57Z","timestamp":1673143377000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06570-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["6570"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06570-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the procedures performed in this study were in accordance with the Clinical Trials Act of the Japanese Ministry of Health, Labor and Welfare and with the 1964 Helsinki declaration and its later amendments. The protocol was approved by the certified review board of Toranomon Hospital and the central ethics committee of the Adequate Treatment of Osteoporosis research group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all the individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"H. Hagino has received lecture fees or grants outside the submitted work from Amgen Inc., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan Co., Ltd., Mitsubishi Tanabe Pharma Corp., Mochida Pharma Corp., Ono Pharmaceutical Co., Ltd., Pfizer Inc., Taisho Pharmaceutical Co., Ltd., Teijin Pharma Co., Ltd., and UCB Japan.T. Sugimoto has received research grants from Asahi Kasei Pharma Corp., Astellas Pharma, Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer, and Teijin Pharma Ltd., as well as consulting fees from Kissei Pharmaceutical Co., Ltd., Shimadzu Corp., and Takeda Pharmaceutical Co., Ltd.S. Tanaka has received lecture fees from Bayer Yakuhin, Amgen Astellas BioPharma K.K., and Research Institute of Healthcare Data Science. He has received consultation fees and outsourcing fees from Daiichi Sankyo Company, Limited, Boehringer Ingelheim, Satt, and the Public Health Research Foundation. He has received research grants from the Japan Agency for Medical Research and Development, the Japanese Ministry of Health Labor and Welfare, the Japanese Ministry of Education, Science, and Technology, and Novo Nordisk. He engaged in a research project of the Japan Agency for Medical Research and Development.T. Sone has received research grants from Astellas Pharma, Eisai, Daiichi-Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan, as well as consulting and\/or lecture fees from Asahi Kasei Pharma, MSD, and Daiichi-Sankyo.T. Nakamura has received personal fees and other from Asahi Pharma, Teijin Pharma, Daiichi-Sankyo Pharma, UCB Pharma, Amgen Inc., Astellas Pharma, and Chugai Pharma, as well as personal fees and others from MERCK.S. Soen has received consulting fees, speaking fees, and\/or honoraria from Asahi Kasei Pharma, Amgen, Astellas Pharma, Daiichi Sankyo, Eli Lilly Japan, Teijin Pharma, and UCB Japan.S. Mori, Y. Mitomo, and K. Takahashi have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}